Corient Private Wealth LLC Has $569,000 Stock Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)

Corient Private Wealth LLC lowered its stake in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 50.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 222,380 shares of the company's stock after selling 224,080 shares during the quarter. Corient Private Wealth LLC's holdings in ImmunityBio were worth $569,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Stephens Inc. AR acquired a new stake in ImmunityBio in the fourth quarter valued at $26,000. Captrust Financial Advisors acquired a new stake in ImmunityBio in the 3rd quarter valued at about $41,000. Virtu Financial LLC bought a new position in ImmunityBio during the third quarter worth about $51,000. Maia Wealth LLC acquired a new position in ImmunityBio during the fourth quarter worth approximately $37,000. Finally, Schechter Investment Advisors LLC bought a new stake in ImmunityBio in the fourth quarter valued at approximately $38,000. Institutional investors own 8.58% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. BTIG Research began coverage on ImmunityBio in a report on Friday, January 10th. They set a "buy" rating and a $6.00 target price on the stock. D. Boral Capital reiterated a "buy" rating and issued a $30.00 price objective on shares of ImmunityBio in a report on Monday. Finally, HC Wainwright restated a "buy" rating and set a $8.00 target price on shares of ImmunityBio in a research note on Thursday, March 13th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $12.19.

Remove Ads

ImmunityBio Price Performance

IBRX traded up $0.09 during trading on Wednesday, hitting $3.05. The stock had a trading volume of 5,228,306 shares, compared to its average volume of 5,597,583. The company has a 50 day moving average price of $3.12 and a 200-day moving average price of $3.59. ImmunityBio, Inc. has a one year low of $2.28 and a one year high of $10.53. The firm has a market cap of $2.60 billion, a price-to-earnings ratio of -3.32 and a beta of 0.82.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.11. The business had revenue of $7.55 million during the quarter, compared to the consensus estimate of $8.74 million. As a group, sell-side analysts predict that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.